Recruiting PHASE3 INTERVENTIONAL 1-arm
NCT06937060
Effect of Semaglutide in Patients With Psoriasis and Obesity (SEMPSO)
Sponsor: The University of Hong Kong
Conditions
Obesity and Overweight Psoriasis (PsO)
Interventions
semaglutide
Updated 2 times since 2025 Last updated: May 7, 2025 Started: Mar 20, 2025 Primary completion: Jul 31, 2026 Completion: Jan 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE3 clinical study on Obesity and Overweight and Psoriasis (PsO), this trial is actively recruiting participants. The trial is conducted by The University of Hong Kong and has accumulated 2 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
2 versions recorded-
Jun 2025 — Present [monthly]
Recruiting PHASE3
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE3
First recorded
Mar 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- The University of Hong Kong
Data source: The University of Hong Kong
For direct contact, visit the study record on ClinicalTrials.gov .